Latest available resultsQuarter ended June 30, 202610-K · August 13, 2026
Filed with the SECRESMED INC
RMDHealthcare
Next reportOctober 28, 2026Analyst forecast 2.715 $/share
Revenue
$1.46B
▲ +8.6% vs prior year% YoY
Net income
$383.43M
▲ +1.0% vs prior year% YoY
EPS
—
Net margin
26.2%
▼ -2.0 percentage points vs prior year pp YoY
Revenue▲ +8.6 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +1.0 %
EPS
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $1.46B | |
| Gross profit | $861.22M | 58.8 % |
| Operating income | $448.71M | 30.7 % |
| Net income | $383.43M | 26.2 % |
| R&D | $105.73M | 7.2 % |
| EPS (diluted) | — | |
| Balance sheet | ||
| Assets | $8.97B | |
| Liabilities | $2.38B | |
| Equity | $6.59B | |
| Cash | $1.47B | |
| Capital | ||
| Shares outstanding | 144.25M | as of 2026-08-10 |
| Public float | — | |
No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.
View 10-K filed 2026-08-13 on SEC ↗